News & Blogs

Commitment to Seniors Opposes Draft Regulations Under the Comprehensive Outbound Investment National Security (COINS) Act

Washington, D.C. – October 22, 2026 – Commitment to Seniors (C2S), a project of American Commitment, opposes the U.S. Treasury Department’s draft regulations under the Comprehensive Outbound Investment National Security (COINS) Act, which would expand restrictions on outbound investment in biopharmaceuticals. American seniors have the most to lose when government policies stand in the way of medical progress. Treasury’s proposed expansion of investment restrictions threatens to do exactly that. By preventing American companies from pursuing…

Learn More

Don’t Ban U.S. Biotech Companies From China

No one wants America to outcompete China than we do. But restricting our biotech industry is no way to achieve that. America has invented some of the world’s most groundbreaking medicines. China is trying to catch up, and our lead in medical innovation could slip. The good news is the rivalry to win the race for the cure for diseases means more medical innovation overall and better health for everyone. That’s why the Treasury Department’s…

Learn More

The COINS Act: Penny Wise, Patient Foolish

Washington has finally figured out that biotechnology is a national security issue. Welcome to the party. The Chinese government has understood this for years, investing aggressively in pharmaceutical research, advanced manufacturing, and the scientific infrastructure that will determine who develops tomorrow’s medicines. While Washington was busy congratulating itself on America’s historic leadership in biotechnology, Beijing was busy building the competition. Now comes the Comprehensive Outbound Investment National Security (COINS) Act. Enacted last December, the law…

Learn More

GLOBE: A World of Bad Ideas for American Patients

Washington has a new idea for lowering prescription drug costs: Let other countries decide what American medicines should cost. It’s an appealing political proposition, particularly when Americans are understandably frustrated by high drug prices. Unfortunately, what sounds like common sense on the campaign trail can turn into very bad medicine once it becomes government policy. The Centers for Medicare & Medicaid Services has finalized its GLOBE model, which would tie the prices of certain Medicare…

Learn More

Update on Foreign Freeloading on American Drug Innovation

The U.S. is the global leader of biomedical innovation, and other nations are not paying their fair share for America’s groundbreaking research and development. Other rich countries use government price controls to limit their spending on brand drugs. President Trump has urged these countries to end the freeloading and start investing. While the U.K. answered the call and agreed to pay more for US brand drugs, other nations, including France, Germany, and Japan, are doubling…

Learn More

Beware the Post-Midterm Price Control Creep

Storm clouds are gathering for Republicans ahead of next month’s midterm elections. If the forecast holds, a divided government could leave Washington gridlocked for two years. Yet one policy idea being floated on Capitol Hill may find support from both congressional Democrats and the White House during the stalemate. For those who favor limited government and competitive markets, the prospect is unnerving. In 2022, President Joe Biden and his allies in Congress passed the Inflation…

Learn More

Buyer Beware: New Medicare Plans Have Fewer Benefits, Higher Costs

It is going to be a tough year for seniors shopping for Medicare coverage. If you don’t choose wisely, you might get hit with surprise bills for your medications, or learn too late that your doctors are out of network. For the third year in a row, major Medicare insurers are pruning some benefits while adding bigger out-of-pocket charges such as deductibles. “Medicare Advantage plans are leaning toward focusing on margin repair,” said Michael Ha,…

Learn More

How MFN pricing in the final GLOBE Model will affect beneficiary OOP costs

Avalere Health’s recently updated analysis of 2023 Medicare Current Beneficiary Survey data suggests that the Global Benchmark for Efficient Drug Pricing (GLOBE) Model would have a very limited impact on OOP costs. We found that: Among fee-for-service (FFS) beneficiaries who used GLOBE-eligible drugs, less than 3,000 have standard Part B OOP cost-sharing exposure because they do not have supplemental insurance. When accounting for the GLOBE Model’s application to approximately 25% of Part B FFS beneficiaries,…

Learn More